RLYB - Rallybio Corporation Stock Price, Fair Value and News

$1.02+0.03 (+3.03%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

RLYB Price Action

Last 7 days

3.0%

Last 30 days

-1.0%

Last 90 days

-9.7%

Trailing 12 Months

-57.5%

RLYB RSI Chart

RLYB Valuation

Market Cap

42.3M

Price/Earnings (Trailing)

-0.63

Price/Sales (Trailing)

8.72

EV/EBITDA

-0.26

Price/Free Cashflow

-0.83

RLYB Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

RLYB Fundamentals

RLYB Revenue

Revenue (TTM)

4.9M

Rev. Growth (Yr)

-36.18%

Rev. Growth (Qtr)

-13.74%

RLYB Earnings

Earnings (TTM)

-67.0M

Earnings Growth (Yr)

37.6%

Earnings Growth (Qtr)

29.38%

RLYB Profitability

EBT Margin

-1330.13%

Return on Equity

-94.57%

Return on Assets

-84.77%

Free Cashflow Yield

-120.67%

RLYB Investor Care

Shares Dilution (1Y)

9.77%

Diluted EPS (TTM)

-1.59

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	5.9M	5.4M	4.9M	0
2023	3.4M	4.8M	5.8M	6.1M
2022	134.0K	391.0K	904.0K	2.0M
2021	141.8K	112.5K	83.3K	54.0K
2020	0	0	0	171.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Rallybio Corporation

Rallybio Corporation, a clinical-stage biotechnology company, engages in identifying, accelerating, and development of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.

CEO	Dr. Stephen Uden M.B, M.D.
WEBSITE	rallybio.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	45

Rallybio Corporation Frequently Asked Questions

What is the ticker symbol for Rallybio Corporation? What does RLYB stand for in stocks?

RLYB is the stock ticker symbol of Rallybio Corporation. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Rallybio Corporation (RLYB)?

As of Fri Nov 22 2024, market cap of Rallybio Corporation is 42.32 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RLYB stock?

You can check RLYB's fair value in chart for subscribers.

Is Rallybio Corporation a good stock to buy?

The fair value guage provides a quick view whether RLYB is over valued or under valued. Whether Rallybio Corporation is cheap or expensive depends on the assumptions which impact Rallybio Corporation's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RLYB.

What is Rallybio Corporation's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Nov 22 2024, RLYB's PE ratio (Price to Earnings) is -0.63 and Price to Sales (PS) ratio is 8.72. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RLYB PE ratio will change depending on the future growth rate expectations of investors.